ライフサイエンスコーパス: immunoglobulin G

1 54 having an inhibitor titer of 34 000 BU/mg immunoglobulin G.

2 ntibody-positive (test) or healthy (control) immunoglobulin G.

3 several serum proteins including albumin and immunoglobulin G.

4 tion 10ng/ml) and selectivity towards human immunoglobulin G.

5 tion ~10ng/ml) and selectivity towards human immunoglobulin G.

6 e-cell cloning and expression of fully human immunoglobulin-G.

7 ks had the lowest seroprevalence of anti-HEV immunoglobulin G (15.3%, 95% confidence interval [CI] 12

8 l 927e (bovine serum albumin), a high-purity immunoglobulin G 1kappa, and a formulated Rituximab.

9 bination of activated platelets and specific immunoglobulin G-adsorbed bacteria are required to induc

10 through 3 years posttransplant, and measured immunoglobulin G against 6 H-Y antigens.

11 The gold waveguides were functionalized with immunoglobulin G against blood group A (anti-A IgG) by f

12 s of immunoglobulin M, immunoglobulin A, and immunoglobulin G against C. difficile toxin A were depre

13 There was an unexpected persistence of immunoglobulin G almost until weaning, potentially indic

14 However, they completely failed to produce immunoglobulin G, although they were not impaired in imm

15 sia, several vaccine/pathogen-specific serum immunoglobulin G and A (IgG and IgA) titers remain relat

16 Immunoglobulin G and A levels were quantified using an e

17 m C3 principally, and also from C4, impaired immunoglobulin G and C1q detection.

18 Peripheral anti-lipopolysaccharide immunoglobulin G and immunoglobulin A responses were sig

19 nasopharyngeal colonization and induction of immunoglobulin G and immunoglobulin A to all antigens te

20 yme-linked immunosorbent assay for anti-HCMV immunoglobulin G and immunoglobulin M and for cIL-10 and

21 94 children and 106 adults were examined for immunoglobulin G and immunoglobulin M antibodies for HEV

22 al peak in the gamma region, with monoclonal immunoglobulin G and lambda light chain detected on immu

23 Multiplexed assay of human immunoglobulin G and M (IgG and IgM) antibodies with EDP

24 Vaccination with PCV13 induces anticapsular immunoglobulin G and opsonophagocytic antibody responses

25 ks demonstrated readily detectable levels of immunoglobulin G and/or immunoglobulin M in human plasma

26 sed the lymphoma B-cell receptors as soluble immunoglobulin Gs and membrane IgMs, and analyzed their

27 in mass from 2846 Da (melittin) to 150 kDa (Immunoglobulin G), and we consider how they are presente

28 NMOSD patients were positive for aquaporin-4-immunoglobulin G, and all sarcoidosis cases were patholo

29 glucose, ascorbic acid human serum protein, immunoglobulin G, and immunoglobulin M), and demonstrate

30 gen-binding (Fab fragment) of monoclonal rat immunoglobulin G; and m-Fab-F, a human recombinant sFab

31 e F(ab')2 and Fc regions of a TRALI-inducing immunoglobulin G anti-major histocompatibility complex (

32 RhD immunoglobulin G (anti-D) administered to pregnant Rh(-)

33 lyte binding interactions between anti-human immunoglobulin G (anti-hIgG) and human immunoglobulin G

34 Polyclonal anti-immunoglobulin G (anti-IgG) secondary antibodies are ess

35 e assessments and had anti-Toxoplasma gondii immunoglobulin G (anti-Toxo IgG) measured by qualitative

36 Immunoglobulin G antibodies (Abs) to Plasmodium falcipar

37 prevalence (17%) of hepatitis E virus (HEV) immunoglobulin G antibodies (anti-HEV) was recently foun

38 nes, correlated directly with B. burgdorferi immunoglobulin G antibodies (P </= .02), suggesting a be

39 nd Trichinella-specific immunoglobulin M and immunoglobulin G antibodies after exposure to implicated

40 Sera were tested for immunoglobulin G antibodies against EBV viral capsid ant

41 Immunoglobulin G antibodies bound to rodent spinal cord

42 tericidal activity (SBA) assay, and anti-STm immunoglobulin G antibodies by enzyme-linked immunosorbe

43 Mutated immunoglobulin G antibodies cross-reactive with both Env

44 lack of BB0405-specific immunoglobulin M or immunoglobulin G antibodies during natural infection, mi

45 Anti-F immunoglobulin G antibodies rose 6.5-15.6-fold, with sig

46 our studies on posttransplant production of immunoglobulin G antibodies targeting cell surface antig

47 ax transmission, we measured total levels of immunoglobulin G antibodies to 5 PvDBP variants and used

48 mmunosorbent assay kits for immunoglobulin M/immunoglobulin G antibodies to herpes simplex virus 1 an

49 ntrations and neutralizing activity of serum immunoglobulin G antibodies to the RSV prefusion (pre-F)

50 ion between the risk of Burkitt lymphoma and immunoglobulin G antibodies was consistent for available

51 itis C therapy in patients carrying anti-HEV immunoglobulin G antibodies, raising 2 major questions:

52 High-titer BBI39 immunoglobulin G antibodies, which have borreliacidal pr

53 thogenesis that features platelet-activating immunoglobulin G antibodies.

54 synthesis of borrelial immunoglobulin M and immunoglobulin G antibody in 100%, 81.1%, 63%, and 88.7%

55 ification and/or the detection of anti-SFTSV immunoglobulin G antibody in sera.

56 Higher immunoglobulin G antibody levels among those seropositiv

57 h Hodgkin lymphoma have significantly higher immunoglobulin G antibody levels than disease-free contr

58 defined a priori as those with subprotective immunoglobulin G antibody levels to >/=66% of vaccines t

59 ot succumb to infection, the detection of an immunoglobulin G antibody response along with observed c

60 No association between total immunoglobulin G antibody responses to any PvDBP variant

61 t assay was used for detecting type-specific immunoglobulin G antibody responses to CMV and herpes si

62 On day 29, 92.9% of vaccinees had an anti-F immunoglobulin G antibody seroresponse.

63 Eight patients with endocarditis had phase I immunoglobulin G antibody titers >800 but did not meet t

64 ing to the presence of highly elevated serum immunoglobulin G antibody titers with a high avidity ind

65 with a faster decline of maternally derived immunoglobulin G antibody to both the EBV viral capsid a

66 ell-based assays for MOG-IgG and aquaporin-4 immunoglobulin G (AQP4-IgG).

67 bivalent antigen-binding fragment regions of immunoglobulin G are sufficient to trigger adverse event

68 or C5-depleted human sera, using anti-mouse immunoglobulin G as the detection antibody.

69 e demonstrated on a direct assay with rabbit immunoglobulin-G as a model system.

70 al OST to glycosylate the Fc domain of human immunoglobulin G at its native 'QYNST' sequon.

71 Serum Borrelia immunoglobulin M and immunoglobulin G at the time of positive Borrelia intrat

72 Only immunoglobulin G avidity index was higher in nontransmit

73 globulin M-positive and low or moderate HCMV immunoglobulin G avidity.

74 ed cases' sera for measles immunoglobulin M, immunoglobulin G, avidity, and plaque reduction neutrali

75 CD14+ monocyte-derived macrophages (MDM) and immunoglobulin G+ B-cell lineage cells, and loss of matu

76 Anti-LPS immunoglobulin G blocked LPS-induced, but not heme-induc

77 control mice, but in test mice the levels of immunoglobulin G bound to the left hippocampus were high

78 long TACI isoform retained surface CD19 and immunoglobulin G, cells transduced with the short TACI i

79 We observed a transient and noninhibitory immunoglobulin G class 2 response against cFVII only in

80 Using 3G5-specific, immunoglobulin G-coated magnetic beads, we isolated peri

81 actose-alpha1,3-galactose, immunoglobulin M, immunoglobulin G, complement, fibrin, tissue factor, fib

82 Albumin levels and total immunoglobulin G concentration were determined by immuno

83 Increases in anticapsular polysaccharide immunoglobulin G concentrations and opsonophagocytic ant

84 us was not associated with serotype-specific immunoglobulin G concentrations or functional antibody t

85 The primary endpoint was serotype-specific immunoglobulin G concentrations values (geometric mean c

86 e higher (P < 0.0001) and the level of bound immunoglobulin G correlated with the seizure scores (R(2

87 a) generated upon digestion with recombinant immunoglobulin G-degrading enzyme of Streptococcus pyoge

88 middle-down MS protocol based on the use of immunoglobulin G-degrading enzyme of Streptococcus pyoge

89 ) by a multiplexed virus-like particle-based immunoglobulin G direct enzyme-linked immunosorbent assa

90 oconversion, defined as a 4-fold increase in immunoglobulin G directed against Cryptosporidium gp15 a

91 d in 2 C1-INH treated patients tested, while immunoglobulin G DSA levels showed decreased binding for

92 ibodies in vivo, and suggest that binding of immunoglobulin G either reduced synaptic localization of

93 infection in vitro that was mediated through immunoglobulin G engagement of Fcgamma receptors.

94 Polymorphisms in the immunoglobulin G Fc receptor II (FcGR) and tumor necrosi

95 ncanavalin, human serum amyloid protein, and Immunoglobulin G) from those that contain at least some

96 Among 34 patients (91.9%) with monoclonal immunoglobulin G gammopathy, 20 (58.8%) had kappa light

97 ecent advances enabling the cloning of human immunoglobulin G genes have proven effective for discove

98 years), geometric mean fold rises (GMFRs) of immunoglobulin G geometric mean concentrations from base

99 A pool of intact ovine immunoglobulin G, herein termed EBOTAb, was prepared fro

100 human immunoglobulin G (anti-hIgG) and human immunoglobulin G (hIgG).

101 T-cell count >500/muL (median, 966/muL) and immunoglobulin G (IgG) >500 mg/dL (median, 727 mg/dL).

102 n the presence of reactive, non-neutralizing immunoglobulin G (IgG) (RNNIg) is the greatest risk fact

103 r inflammation paralleled the development of immunoglobulin G (IgG) against malonyldialdehyde (MDA) a

104 FcgammaRIIA activation is dependent on immunoglobulin G (IgG) and alphaIIbbeta3 engagement.

105 specifically incorporated into an anti-CXCR4 immunoglobulin G (IgG) and conjugated to an auristatin t

106 DENV-specific immunoglobulin G (IgG) and DENV-1-4 serotype-specific ne

107 rum was evaluated for PcrV- and Psl-specific immunoglobulin G (IgG) and for cytotoxicity and opsonoph

108 Immunoglobulin G (IgG) and Hepatitis B surface Antigen (

109 the selective naked-eye detection of rabbit immunoglobulin G (IgG) and human-prostate-specific antig

110 says to determine the prevalence of anti-HEV immunoglobulin G (IgG) and IgM among 10,569 French blood

111 f resting B cells to plasmablasts as well as immunoglobulin G (IgG) and IgM secretion.

112 Sera were tested for immunoglobulin G (IgG) and immunoglobulin A (IgA) antibo

113 protective role for both Chlamydia-specific immunoglobulin G (IgG) and polymorphonuclear neutrophils

114 zing (neut), NI, immunoglobulin A (IgA), and immunoglobulin G (IgG) anti-HA antibody.

115 Immunoglobulin G (IgG) antibodies against intact merozoi

116 Immunoglobulin G (IgG) antibodies against pertussis toxi

117 en to estimate the half-lives of circulating immunoglobulin G (IgG) antibodies and IgG antibody-secre

118 During pregnancy immunoglobulin G (IgG) antibodies are transferred from m

119 Serum immunoglobulin G (IgG) antibodies have been implicated i

120 Current methods for producing immunoglobulin G (IgG) antibodies in engineered cells of

121 les to effective CNS delivery of full length immunoglobulin G (IgG) antibodies include transport acro

122 The immunoglobulin G (IgG) antibodies to all 3 MMR antigens

123 Dengue immunoglobulin G (IgG) antibodies were measured at basel

124 TT immunoglobulin G (IgG) antibodies were quantified and ge

125 The relationship between immunoglobulin G (IgG) antibody and both interferon gamm

126 seropositivity for CMV and the level of CMV immunoglobulin G (IgG) antibody are associated with all-

127 We developed an HCV immunoglobulin G (IgG) antibody avidity assay by modifyi

128 ntrations, cell-mediated immunity (CMI), and immunoglobulin G (IgG) antibody avidity were assessed at

129 We determined pneumococcal serum immunoglobulin G (IgG) antibody concentrations against 1

130 higher levels of anti-cytomegalovirus (CMV) immunoglobulin G (IgG) antibody have been associated wit

131 iomolecular interactions of protein A/G with immunoglobulin G (IgG) antibody.

132 ened 263 solid-organ recipients for anti-HEV immunoglobulin G (IgG) at transplantation.

133 CMV immunoglobulin G (IgG) avidity and CMV enzyme-linked imm

134 fication and detection of antibodies such as immunoglobulin G (IgG) because of its quadrivalent domai

135 ng rabbit complement (rSBA) and NmA-specific immunoglobulin G (IgG) by enzyme-linked immunosorbent as

136 tivation instigates MZ B-cell proliferation, immunoglobulin G (IgG) class switching, and plasmablast

137 he measurement of immunoglobulin M (IgM) and immunoglobulin G (IgG) classes of antibodies separately.

138 Anti-polyribosylribitol phosphate (PRP) immunoglobulin G (IgG) concentration and the frequency o

139 We assessed anti-MenA immunoglobulin G (IgG) concentrations (n = 200) and, usi

140 , the proportion of children with protective immunoglobulin G (IgG) concentrations against the infect

141 sition and prevalence, and serotype-specific immunoglobulin G (IgG) concentrations were assessed.

142 c opsonophagocytic activity (OPA) titers and immunoglobulin G (IgG) concentrations were determined.

143 proportion of iRBCs recognized by autologous immunoglobulin G (IgG) correlated with the parasite clea

144 a Eudragit L100 copolymer layer followed by immunoglobulin G (IgG) covalent immobilization, an IgG/a

145 Immunoglobulin G (IgG) cross-linking with Fc gamma recep

146 on provided no advantage in sensitivity over immunoglobulin G (IgG) detection.

147 tags in a competitive immunoassay for rabbit immunoglobulin G (IgG) detection.

148 The delayed production of gB-specific immunoglobulin G (IgG) during primary HCMV infection is

149 ZIKV-NS1 immunoglobulin M (IgM) and immunoglobulin G (IgG) ELISAs combined can detect ZIKV i

150 Prototype immunoglobulin M (IgM)/immunoglobulin G (IgG) ELISAs were similarly developed t

151 hSBA, rSBA, and immunoglobulin G (IgG) enzyme-linked immunosorbent assay

152 rabbit complement and by a group A-specific immunoglobulin G (IgG) enzyme-linked immunosorbent assay

153 iter (GMTs) and 4-fold rise of anti-Vi serum immunoglobulin G (IgG) enzyme-linked immunosorbent assay

154 ts for HEV detection: the MP Diagnostics HEV immunoglobulin G (IgG) enzyme-linked immunosorbent assay

155 Immunoglobulin G (IgG) Fc N-glycosylation affects antibo

156 Immunoglobulin G (IgG) formed during pregnancy against h

157 autoimmune conditions and consists of pooled immunoglobulin G (IgG) from healthy donors.

158 Total immunoglobulin G (IgG) from individuals residing in mala

159 The effects of immunoglobulin G (IgG) from patients with the antiphosph

160 of Blood, Arman et al show that bacteria use immunoglobulin G (IgG) from plasma to engage platelet su

161 Aberrant serum immunoglobulin G (IgG) glycosylation and its immunomodul

162 study we demonstrate the potential value of Immunoglobulin G (IgG) glycosylation as a novel prognost

163 N-linked glycans on immunoglobulin G (IgG) have been associated with pathoge

164 endent Fc domain binding protein that buries immunoglobulin G (IgG) His-433.

165 Immunoglobulin G (IgG) is a central mediator of host def

166 Immunoglobulin G (IgG) is a major effector molecule of t

167 In clones producing intact immunoglobulin G (IgG) lambda antibodies (containing pai

168 were tested for anti-HPV-16 and anti-HPV-18 immunoglobulin G (IgG) levels by an L1 virus-like partic

169 e assessed pre-malaria season PfRH5-specific immunoglobulin G (IgG) levels in 357 Malian children and

170 lained by >10-fold increases in PPS-specific immunoglobulin G (IgG) levels in Pneumovax-immunized age

171 Consistent with previous reports, immunoglobulin G (IgG) levels remained stable during the

172 , we tested plasma immunoglobulin A (IgA) or immunoglobulin G (IgG) levels specific for antigens in 9

173 Immunoglobulin G (IgG) levels to schizont extract, meroz

174 Serotype-specific immunoglobulin G (IgG) levels were determined in serum s

175 ophil counts, and increased filaria-specific immunoglobulin G (IgG) levels; these findings were thoug

176 e fragment crystallizable (Fc) region of the immunoglobulin G (IgG) mAb, HuM195, targeting the leukem

177 amma receptors (FcgammaRs), the Fc domain of immunoglobulin G (IgG) mediates a wide spectrum of immun

178 Immunoglobulin G (IgG) monoclonal antibodies (mAbs) are

179 ariate genome-wide association studies of 23 immunoglobulin G (IgG) N-glycosylation phenotypes.

180 We investigated the effect of FVIII-specific immunoglobulin G (IgG) on FVIII half-life in a cohort of

181 It is speculated that immunoglobulin G (IgG) plays a regulatory role in allerg

182 ic assay, we compared the estimated anti-HEV immunoglobulin G (IgG) prevalence and risk factors for a

183 For higher immunoglobulin G (IgG) reactivity to EBV-viral capsid an

184 The CD32a immunoglobulin G (IgG) receptor (Fcgamma receptor IIa) i

185 Affinity-purified immunoglobulin G (IgG) recognizing motif 1 abolished bio

186 e able to disseminate systemically to induce immunoglobulin G (IgG) response, which primarily targete

187 ecificity of plasma antibodies revealed that immunoglobulin G (IgG) responses against the glycoprotei

188 Heat maps for human immunoglobulin G (IgG) responses for each village and su

189 ntibodies had waned and vaccine Env-specific immunoglobulin G (IgG) responses in vaccinees were highe

190 f T(FH) cells, germinal center responses and immunoglobulin G (IgG) responses to acute viral infectio

191 Immunoglobulin G (IgG) responses to AM increased signifi

192 Here we studied naturally acquired immunoglobulin G (IgG) responses to GBS capsular polysac

193 viral responses consisting of total specific immunoglobulin G (IgG) responses, neutralizing antibody

194 .6%, respectively, showed anti-rubella virus immunoglobulin G (IgG) seroprotection.

195 ies depend greatly on the composition of the immunoglobulin G (IgG) structure, both in terms of prima

196 d 4 years off IS, and, at these time points, immunoglobulin G (IgG) subclass and C1q binding activity

197 Group A-specific immunoglobulin G (IgG) subclass response was characteriz

198 nts from the ICONA Study with at least 1 CMV immunoglobulin G (IgG) test available without active CMV

199 Serum immunoglobulin G (IgG) titers to 28 pneumococcal protein

200 s, we observed that the virus scaffolds with immunoglobulin G (IgG) to form immune complexes that pro

201 Transplacental transfer of maternal immunoglobulin G (IgG) to the fetus helps to protect aga

202 Levels of immunoglobulin G (IgG) to VSA were not affected by HIV s

203 Anti-HDV immunoglobulin G (IgG) was sequentially determined in 37

204 tric focused (IEF) cerebrospinal fluid (CSF) immunoglobulin G (IgG) was used in combination with next

205 ree-dimensional (3D) ordered arrays of human immunoglobulin G (IgG) were fabricated using well-define

206 Enzymatically released N-glycans from human immunoglobulin G (IgG) were used as the test sample.

207 nt assay (ELISA), immunoglobulin M (IgM) and immunoglobulin G (IgG) Western blots (WBs), and an ELISA

208 ds, (2) anti-B19V immunoglobulin M (IgM) and immunoglobulin G (IgG), (3) anti-VP1 IgG avidity, (4) an

209 haracterize the expression of membrane-bound immunoglobulin G (IgG), a fluorophore-labeled anti-mouse

210 d from bovine fetuin, polyclonal human serum immunoglobulin G (IgG), and human alpha1-acid glycoprote

211 inal center responses, lacked virus-specific immunoglobulin G (IgG), and were unable to resolve chron

212 -sectional analysis of serum anti-chlamydial immunoglobulin G (IgG), behavioral factors, and microbio

213 Serum immunoglobulin A (IgA) and immunoglobulin G (IgG), fecal IgA, IgA antibody-secretin

214 RV-specific immunoglobulin G (IgG), IgA, and neutralizing activity i

215 Sera were tested for anti-RUBV immunoglobulin G (IgG), IgG avidity, and IgG response to

216 Tests for measles immunoglobulin G (IgG), IgG avidity, measurement of meas

217 Levels of total immunoglobulin G (IgG), immunoglobulin M (IgM), and IgG

218 es of these ZnO NWs were modified with mouse immunoglobulin G (IgG), infused through the second micro

219 wed both specific immunoglobulin M (IgM) and immunoglobulin G (IgG), whereas retrospective analysis o

220 interaction sites on lamin A identified the immunoglobulin G (IgG)-like domain as an interaction hot

221 arm autoimmune hemolytic anemia, circulating immunoglobulin G (IgG)-opsonized blood cells are cleared

222 gocytosis and endocytosis, which internalize immunoglobulin G (IgG)-opsonized particles and polyvalen

223 mmunoassay (CLIA) with a high threshold, and immunoglobulin G (IgG)-specific CLIA with low threshold.

224 streptavidin, barstar-dibarnase and Z domain-immunoglobulin G (IgG).

225 ased class switched memory B cells and serum immunoglobulin G (IgG).

226 and clearance of biopharmaceuticals such as immunoglobulin G (IgG).

227 identification and destruction properties of immunoglobulin G (IgG).

228 n is reported for selective binding of human immunoglobulin G (IgG).

229 n-protein interfaces in the GB1 complex with immunoglobulin G (IgG).

230 for regions contacting and interacting with immunoglobulin G (IgG).

231 for the sensitive and selective detection of immunoglobulin G (IgG).

232 ADAMTS13 autoantibodies (mAbs) by cloning an immunoglobulin G (IgG)4kappa- and IgG4lambda-Fab library

233 antibody (DSA) testing, it is unclear which immunoglobulin-G (IgG) DSA positive patients will fail.

234 sine residues at protein-protein interfaces, immunoglobulin-G (IgG) was conjugated to fluorinated pyr

235 n A [IgA]) and cellular (NV-specific IgA and immunoglobulin G [IgG] antibody-secreting cells and tota

236 EIA seroconversion in 11/17 (65%) patients (immunoglobulin G [IgG]>IgA>IgM) and SRA seroconversion i

237 d interface for the attachment of monoclonal immunoglobulin G (IgGNS1) and to favor specific detectio

238 therapeutics, e.g., monoclonal antibodies or immunoglobulins G (IgGs), demands improved techniques fo

239 Serum total free light chain, immunoglobulin G, immunoglobulin A, and immunoglobulin M

240 ncreased immunoglobulin G index-the level of immunoglobulin G in the cerebrospinal fluid compared to

241 ple sclerosis and reasons for variability in immunoglobulin G index are not known.

242 absence of oligoclonal bands (n = 3026) and immunoglobulin G index levels (n = 938), followed by a r

243 of the immunoglobulin heavy chain locus with immunoglobulin G index reaches strong evidence for assoc

244 nce of oligoclonal bands and/or an increased immunoglobulin G index-the level of immunoglobulin G in

245 band positive and 7.75% of the variation in immunoglobulin G index.

246 major histocompatibility complex region with immunoglobulin G index: the rs9271640*A-rs6457617*G hapl

247 Maternal immunoglobulin G is actively transported across the plac

248 ed determination of bovine casein and bovine immunoglobulin G is carried out in milk samples yielding

249 Human immunoglobulin G isotype 4 (IgG4) antibodies (Abs) are p

250 ean fluorescence intensity (MFI) values, and immunoglobulin G isotype was determined.

251 Finally, we showed that intravenous immunoglobulin G (IVIG) treatment significantly reduced

252 risk, International Staging System stage III immunoglobulin G lambda multiple myeloma (MM).

253 iple myeloma was based on the presence of an immunoglobulin G lambda serum M protein (4,784 mg/dL) an

254 CSF immunoglobulin G level was elevated (30.1 mg/dL; normal,

255 ap during late pregnancy, pertussis-specific immunoglobulin G levels decreased significantly 9-15 mon

256 d not result in significant changes in total immunoglobulin G levels or autoantibodies.

257 Inhibitory antibodies correlated with total immunoglobulin G levels to the EBA-175 binding domain (r

258 circulating B-cell, autoantibody, and total immunoglobulin G levels were monitored following depleti

259 cted, nor were anti-tetanus and anti-measles immunoglobulin G levels.

260 Here we combined immunoglobulin G-mediated immobilization of one cell-sur

261 Neuromyelitis optica-immunoglobulin G (NMO-IgG) binds to aquaporin-4 (AQP4) w

262 Either total anti-HBc or anti-HBc immunoglobulin G (not immunoglobulin M) test should be u

263 on geometric mean titre of LT-specific serum immunoglobulin G of 3400.29, compared with 315.41 in the

264 p < 0.001), presence of cerebrospinal fluid immunoglobulin G oligoclonal bands (OCB; HR = 3.69, 95%

265 ificantly higher plasma anti-influenza virus immunoglobulin G (P < .001) and immunoglobulin A (P < .0

266 o day 120 after transplantation, in anti-CMV immunoglobulin G-positive donor and recipient pairs.

267 esponse in children aged >/=3 years produced immunoglobulin G predominantly, but immunoglobulin M was

268 affinity to all types of human and nonhuman immunoglobulin G, predominantly through attachment to th

269 ion (CD44 and CD86 expression), constitutive immunoglobulin G production, and secretion of the proinf

270 al, plasma cell marker CD138 expression, and immunoglobulin G production.

271 le of Chlamydia-specific immunoglobulin M or immunoglobulin G production.

272 isition of anti-STm-lipopolysaccharide (LPS) immunoglobulin G (r = 0.329 [95% confidence interval, .5

273 In a two-stage study we investigated Immunoglobulin G reactivity in plasma from MDS, Acute My

274 nterrogated CLL membrane-specific autologous immunoglobulin G reactivity.

275 is commonly determined by measuring specific immunoglobulin G (RV IgG).

276 T-cell subsets and immunoglobulin G seropositivity for CMV, EBV, herpes-sim

277 ociations between antibody to HEV (anti-HEV) immunoglobulin G seropositivity indicating past or recen

278 We measured immunoglobulin G seroreactivity against 10 polyomaviruse

279 Analysis of purified immunoglobulin G showed functional growth inhibitory act

280 inked dimer fused to the Fc portion of mouse immunoglobulin G (sP-selectin-Fc).

281 Kingdom between 1987 and 2007 with known CMV immunoglobulin G status were identified from the U.K. Tr

282 Here, we studied isotypes, immunoglobulin G subclasses, and apparent affinities of

283 Each immunized mouse had substantial immunoglobulin G targeting the challenge strains, indica

284 ed with a higher total glycoprotein-specific immunoglobulin G titer.

285 nical oral-health examination, and had serum immunoglobulin G titers measured against 19 periodontal

286 Elevated serum immunoglobulin A and immunoglobulin G titers were associated with partial pro

287 Specific antipneumococcal immunoglobulin G to 27 pneumococcal protein antigens and

288 en their peripartum and follow-up levels for immunoglobulin G to pertussis toxin (21.48 [95% confiden

289 e adjustment, very high IgG aCL levels (>100 immunoglobulin G-type phospholipid units; relative risk

290 size of myofiber diameters, reduced myofiber immunoglobulin G uptake, and reduced muscle wasting at 3

291 a result, isotopic resolution of monoclonal immunoglobulin G was achieved, and we have established a

292 sma samples in which anti-EBOV nucleoprotein immunoglobulin G was detected.

293 n a second antibody, i.e. a HRP-labeled anti-immunoglobulin G, was deposited onto the biosensor.

294 associated changes have been recognized for immunoglobulin G, we sought to demonstrate the clinical

295 Subgingival P. endodontalis levels and serum immunoglobulin G were associated with a higher EL score.

296 ession or deposition of immunoglobulin M and immunoglobulin G were found in xenoperfused tissues of w

297 assay (EIA) followed by immunoglobulin M and immunoglobulin G Western blots, performs well in late-st

298 croarray antibody capture assay for anti-HDV immunoglobulin G wherein recombinant HDV delta antigen i

299 mice had increased serum levels of anti-ENO1 immunoglobulin G, which bound the surface of carcinoma c

300 model protein in human serum, that is, human immunoglobulin G, with the aim to demonstrate a virtuall